Table 1.
Demographic data of patients
| Patient no. | Age (years) | Sex | Symptoms (months)a | Siteb | Intraoperative culturec | Beadd | Systemic antibioticsd | Bead removal | Follow-up (years) | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | M | 12 | Hum P, S | MRSA | VANCO beads + rods | Teikoplanin | 2 months | 6 | Twice, re-debrid |
| 2 | 48 | M | 24 | TIib D | Staphylococcus aureus | VANCO | Fuscidic A + CIPRO | 2 months | 4.5 | – |
| 3 | 15 | M | 2 | Fem S | MRSA | VANCO | Teikoplanin | 2 months | 5 | – |
| 4 | 18 | F | 2.5 | Fem S | Coag (−) Staphylococcus | VANCO | Fuscidic A + CIPRO | 2 months | 3.5 | – |
| 5 | 35 | M | 2 | Rad P | S. aureus | VANCO | Fuscidic A + CIPRO | 2 months | 2.5 | – |
| 6 | 13 | M | 1 | Fem P, septic art. | S. aureus | VANCO | Teikoplanin + CIPRO | 2 months | 4.5 | – |
| 7 | 40 | F | 36 | Tib P,D | S. aureus, Klebsiella | VANCO + GENTA | Teikoplanin + CIPRO | 2 months | 4.5 | Once, re-debrid |
| 8 | 74 | F | 9 | Rad P | S. aureus | VANCO | Teikoplanin + CIPRO | 2 months | 3 | – |
| 9 | 63 | M | 4 | Both Fem P/Hip | MRSA | VANCO | Teikoplanin + CIPRO | 2 months | 3 | – |
| 10 | 15 | M | 60 | Fem S | S. aureus | VANCO | TMP/SMX | 1 month | 5 | – |
| 11 | 35 | F | 4 | Fem S | S. aureus | VANCO | Fuscidic A + CIPRO | 2 months | 2 | – |
| 12 | 36 | M | 42 | Hum S, D | S. aureus | VANCO beads + rods | Teikoplanin | 3 months | 4 | – |
| 13 | 35 | F | 48 | Tib S | S. aureus | VANCO beads + rods | Teikoplanin | 2 months | 3 | – |
| 14 | 50 | M | 8 | Fem P | S. aureus | VANCO | VANCO | 2 months | 3 | – |
| 15 | 25 | M | 96 | Fem S, D | S. aureus | VANCO beads + rods | Teikoplanin + FuscidicA | 2 months | 4 | – |
| 16 | 16 | M | 12 | Fem P | S. aureus | VANCO | Fuscidic A + CIPRO | 2 months | 3 | – |
| 17 | 73 | F | 96 | Fem D | S. aureus | VANCO | Imipenem + CIPRO | 2 months | 2 | – |
| 18 | 50 | M | 12 | Midfoot | S. aureus | No beads | Teikoplanin + CIPRO | 2 months | 4 | – |
| 19 | 20 | M | 3 | Tib D | Pseudomonas aeruginosa | VANCO beads + rods | CIPRO + Cefuroxime | 2 months | 4 | – |
| 20 | 56 | F | 72 | Fem D | S. aureus | VANCO | Fuscidic A + CIPRO | 2 months | 2 | – |
| 21 | 12 | M | 96 | Fem S,D | S. aureus | VANCO | VANCO | 2 months | 4 | – |
| 22 | 20 | M | 12 | Fem S | Enterobacter | VANCO | Teikoplanin | 2 months | 5 | Once, re-debrid |
| 23 | 50 | M | 12 | Fem P/Hip | MRSA | VANCO | Teikoplanin + TMP/SMX | 2 months | 4 | – |
| 24 | 39 | M | 96 | Tib D | S. aureus | VANCO | Teikoplanin | 3 weeks | 5 | – |
| 25 | 5 | M | 3 | Tib P | Enteroccoci | VANCO | Ceftriaxone | 2 months | 2 | – |
| 26 | 13 | M | 3 | Hum P | S. aureus | VANCO | Fuscidic A + CIPRO | 2 months | 2 | – |
aSymptoms: The duration of syptoms upon admission
bHum, Humerus; Rad, radius; Fem, femur; Tib, tibia; P, proximal; S, shaft; D, distal
cMRSA, methicillin-resistant Staphylococcus aureus
dVANCO, vancomycin; GENT, gentamicin; CIPRO, ciprofloxacin; TMP/SMX, trimethoprim-sulfamethoxazole